For telehealth operators, however, the real challenge is not simply deciding whether to offer NAD+ programs. It is about understanding how those programs should be structured operationally, clinically, and in compliance from the beginning.
Delivery format plays a major role in that decision.
The way NAD+ is delivered affects the patient experience, pharmacy infrastructure, provider workflows, onboarding complexity, and even marketing strategy. Some formats are highly compatible with remote-first telehealth programs, while others introduce additional operational requirements that make scaling more difficult.
One of the most telehealth-friendly formats currently gaining traction is the NAD+ sublingual tablet, commonly referred to as an orally disintegrating tablet or ODT. These products are designed to dissolve in the mouth rather than be swallowed, as with traditional capsules, or administered via injection.
For operators evaluating wellness program expansion, understanding how NAD+ ODT delivery works and where its advantages and limitations exist is becoming increasingly important.
NAD+ therapy is quickly becoming one of the most discussed categories in longevity and wellness telehealth. But for operators building these programs, the conversation is no longer just about the ingredient itself. Delivery format now affects everything from patient adherence and pharmacy operations to compliance exposure and overall program scalability.
Key Takeaways
- NAD+ sublingual tablets are compounded orally disintegrating tablets (ODTs) designed to dissolve under the tongue
- ODT delivery offers a needle-free format that aligns well with telehealth-based wellness programs
- Delivery format impacts patient experience, operational complexity, pharmacy requirements, and adherence
- Compounded NAD+ products carry important compliance and regulatory considerations
- Educational, compliance-aware communication is essential when marketing NAD+ programs
- Telehealth operators should understand the operational differences between ODT, injectable, and IV delivery models
What Is a NAD+ Sublingual Tablet?
A NAD+ sublingual tablet is a compounded dosage form designed to dissolve under the tongue or inside the mouth instead of being swallowed whole. These products are commonly categorized as orally disintegrating tablets (ODTs), meaning they dissolve rapidly after administration without requiring water.
In telehealth-based wellness programs, this delivery format is often positioned as a more convenient and lower-friction alternative to injectable therapies. Patients who are hesitant around needles or who prefer simpler daily routines may find dissolvable formats easier to integrate consistently.
From an operational standpoint, this matters more than many operators initially realize.
Program adherence is heavily influenced by convenience. The easier a therapy feels to incorporate into a daily routine, the more likely patients are to remain engaged over time. That is one reason ODT formats have gained traction across multiple wellness categories, particularly those designed around recurring subscription-based care models.
Sublingual delivery also introduces important formulation considerations. Unlike traditional swallowed capsules that pass through the digestive tract, ODT products dissolve via oral mucosal absorption pathways before entering the systemic circulation. However, operators should understand that compounded formulations can vary significantly depending on the pharmacy, excipient profile, manufacturing standards, and overall formulation quality.
Not all ODT products are operationally equivalent.
For telehealth businesses, pharmacy selection becomes one of the most important infrastructure decisions in the entire program architecture.
Why NAD+ Delivery Format Matters for Telehealth Programs
For many telehealth operators, the biggest misconception about NAD+ programs is assuming the ingredient itself is the primary differentiator.
In reality, delivery format often shapes the scalability of the business model far more than the compound alone.
Different delivery methods create different operational burdens. Some require extensive patient education, injection training, sterile handling procedures, or complex shipping logistics. Others fit naturally into remote-first care models with significantly lower onboarding friction.
This is one reason ODT delivery has become increasingly attractive for telehealth-based wellness programs.
Compared to injectable formats, sublingual tablets typically reduce operational complexity. There are no needles-or-sharps disposal requirements and fewer patient-training barriers during onboarding. For operators focused on accessibility and scalability, those differences can materially affect patient retention and support workflows.
The patient experience also changes considerably.
Many wellness consumers are interested in convenience-oriented care models that feel simple, manageable, and easy to maintain consistently. ODT products align naturally with that expectation because they eliminate several friction points commonly associated with injectable therapies.
At the same time, operators should avoid oversimplifying the conversation into “better versus worse” delivery narratives. Each format has different operational tradeoffs, and program design should ultimately align with provider oversight, pharmacy quality, patient suitability, and the overall clinical structure of the business.
The strongest telehealth programs are usually designed around operational clarity rather than marketing hype.
How ODT Delivery Works
When an NAD+ ODT dissolves under the tongue or inside the mouth, the compound interacts with the oral mucosal tissue before entering systemic circulation. This route is commonly referred to as sublingual or buccal absorption, depending on where the tablet is placed.
From a telehealth operations perspective, the key point is not making exaggerated absorption claims. It is understood that delivery mechanics can influence how a therapy is experienced and administered within a patient workflow.
Discussions about NAD+ bioavailability have become increasingly common online, but operators should approach them carefully. Dedicated comparative research between compounded NAD+ ODT products and injectable delivery formats remains limited, and formulation quality can substantially affect performance characteristics.
That distinction matters because wellness marketing often turns scientific terminology into oversimplified sales messaging.
Responsible operators should avoid making unsupported comparative claims around efficacy, superiority, or guaranteed outcomes. Instead, educational content should focus on accurately explaining:
- How the delivery format works,
- What operational differences exist?
- And where formulation quality becomes important.
This type of communication is not only more compliant. It is also more sustainable from a brand trust perspective.
Consumers are becoming increasingly skeptical of exaggerated longevity marketing, especially in categories connected to optimization and anti-aging culture. Clearer, more balanced communication often performs better in the long term because it feels more credible and transparent.
NAD+ ODT vs Injectable Delivery Models
One of the biggest operational decisions telehealth operators face is whether to structure NAD+ programs around oral dissolvable formats or injectable delivery.
Both models come with different infrastructure requirements.
Injectable NAD+ programs typically involve higher operational complexity. Subcutaneous delivery requires patient education around injection technique, sterile handling, storage, and sharps disposal. Intramuscular and IV-based models may require in-clinic administration or more extensive provider oversight, depending on the program's structure.
ODT formats reduce much of that friction.
Because sublingual tablets do not require needles or sterile injection supplies, onboarding is often simpler and easier to scale operationally. Shipping logistics are also generally more straightforward compared to injectable fulfillment workflows involving syringes, alcohol swabs, sharps containers, or temperature-sensitive handling requirements.
For telehealth-first operators, these differences matter significantly.
Programs that minimize onboarding complexity often result in fewer support tickets, reduced patient hesitation, and smoother recurring fulfillment workflows. That does not automatically make one format clinically preferable in every situation, but it does affect the business infrastructure required to support the program successfully.
This is why many wellness operators view ODT delivery as highly compatible with remote-first care models focused on accessibility and convenience.
Compliance Considerations for NAD+ ODT Programs
NAD+ sublingual tablets exist inside a sensitive compliance environment because they are compounded prescription products rather than FDA-approved finished medications.
Operators building these programs need to clearly understand that distinction.
Compounded therapies entail specific operational obligations, including provider oversight, pharmacy partnerships, patient communication standards, and marketing restrictions. Every layer of the program, from onboarding flows to educational content, should be carefully structured to avoid misleading or non-compliant messaging.
One of the most common mistakes in wellness marketing is turning educational content into implied medical claims.
Responsible communication should avoid:
- disease-treatment language,
- guaranteed outcomes,
- exaggerated anti-aging promises,
- before-and-after transformation framing,
- or unsupported efficacy statements.
This becomes especially important in paid advertising environments where platform policies, FTC substantiation expectations, and healthcare marketing regulations can overlap in complicated ways.
For telehealth operators, compliance is not just a legal checkpoint added at the end of a campaign review. It should be part of the operational design process from the beginning.
The most durable wellness brands are usually the ones that communicate clearly without relying on sensationalism.
That broader industry shift is also influencing how healthcare technology platforms approach wellness education. Companies like Bask Health increasingly emphasize educational, operator-focused content strategies built around transparency, responsible communication, and long-term trust rather than aggressive marketing narratives.
Final Thoughts
The growth of NAD+ sublingual tablets reflects a larger shift happening across wellness telehealth.
Consumers are increasingly drawn toward care models that feel more accessible, flexible, and easier to integrate into everyday routines. At the same time, operators are looking for delivery formats that reduce operational friction while still supporting scalable program infrastructure.
ODT delivery fits naturally into both trends.
For telehealth businesses, however, the opportunity is not simply about offering a trending wellness product. Sustainable program growth depends on understanding how delivery format affects patient onboarding, provider workflows, pharmacy partnerships, compliance exposure, and long-term operational scalability.
As the NAD+ market continues to evolve, the companies that succeed in the long term will likely be the ones that balance innovation with operational discipline. In a category filled with hype-heavy messaging and exaggerated promises, grounded education and responsible communication are becoming competitive advantages in their own right.
References
- Federal Trade Commission. (2023, July). The FTC’s Endorsement Guides: What People Are Asking. U.S. Federal Trade Commission. https://www.ftc.gov/business-guidance/resources/ftcs-endorsement-guides-what-people-are-asking
- StatPearls Publishing. (2025). Telemedicine. In StatPearls. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK560743/
- U.S. Food and Drug Administration. (2025, January). Human drug compounding laws. U.S. Department of Health & Human Services. https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
- U.S. Food and Drug Administration. (2023, January 4). Step 3: Clinical research. U.S. Department of Health & Human Services. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
- Doraiswamy, S., Abraham, A., Mamtani, R., & Cheema, S. (2020). Use of telehealth during the COVID-19 pandemic: Scoping review. Journal of Medical Internet Research, 22(12), e24087. https://pmc.ncbi.nlm.nih.gov/articles/PMC7238909/
